BofA analyst Sachin Jain raised the firm’s price target on Novartis (NVS) to $178 from $163 and keeps a Buy rating on the shares. The firm raised its target to reflect recent upgrades to its view of the odds of success for key pipeline assets including remibrutinib, del-desiran, del-brax and pelacarsen, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis: Strengthened Late-Stage Pipeline Underpins Upgraded CHF140 Target and Buy Rating
- Novartis Stock (NVS) Climbs after Paying $3B for “Mutant”- Fighting Breast Cancer Drug
- Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics
- Novartis initiated with a Market Perform at Bernstein
- Novartis Raises $11 Billion in Multi-Tranche U.S. Bond Offering